Plain-English translation of NCT05026983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and for people with melanoma that has spread to the brain or the fluid around the brain and spinal cord. The trial focuses on patients whose melanoma has a specific genetic change (called a BRAF V600 mutation) and whose cancer is getting worse despite previous treatments. Researchers want to see if this two-drug combination, given at higher doses than usual, can slow or stop the cancer's growth in the brain.
Melanoma that spreads to the brain is very difficult to treat because these medications don't always reach the brain well enough to fight the cancer there. This trial is testing whether higher doses of this medication combination can penetrate the brain better and work more effectively for patients whose cancer has already progressed.
You likely qualify if…
You likely don't qualify if…
You will take two pills by mouth — one once daily and one twice daily — in 28-day cycles as long as the treatment is working and side effects are manageable. During the trial, you'll have regular clinic visits for blood tests, brain imaging scans, and check-ins about how you're feeling and any side effects. After you finish treatment, you'll be followed up 30 days later and then every 12 weeks to see how you're doing long-term.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States